Fibrinolytic capacity and risk of myocardial infarction

Fibrinolysis

Volumn 10, Issue SUPPL. 2, 1996, Pages 9-12

  Van Der Bom, J G ^a,b   Bots, M L ^a   Haverkate, F ^b   Grobbee, D E ^a   Kluft, C ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; FIBRINOLYSIS; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029907850     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80035-X     Document Type: Conference Paper

References (25)

1. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-79.
2. Gram J, Jespersen J. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulin characterizes a risk group among young survivors of acute myocardial infarction. Thromb Haemostas 1987;57:137-9.
3. Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Scand 1987;221:149-53.
4. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990;6:525-8.
5. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation 1993;88:2030-4.
6. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
7. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-8.
8. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen Activator Inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;4:3-9.
9. Geppert A, Backmann R, Graf S, Hornykeywycz S, Lang I, Schuster E, Binder BR, Huber K. Tissue type plasminogen activator and type 1 plasminogen activator inhibitor inpatients with coronary artery disease - relations to clinical variables and cardiovascular disease. Fibrinolysis 1995;9 (Suppl 2): 109-13.
10. Kluft C. Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1): Conditions and therapeutic targets. Fibrinolysis 1994; 8, suppl 2: 1-7.
11. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Associations of fibrinolytic parameters with early atherosclerosis. Circulation 1995;91:284-90.
12. Smith FB, Lee AJ, Rumley A, Fowkes FGR, Lowe GDO. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. 1995;115:35-43.
13. Emeis JJ. Mechanisms involved in short-term changes in blood levels of t-PA. In: Kluft C, ed. Tissue-type plasminogen activator (t-PA): physiological and clinical aspects. Florida: CRC-Press, 1988:21-35
14. Brommer EJP. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards. Thromb Res 1984; 34: 109-115.
15. Potter van Loon BJ, Rijken DC, Brommer EJP, van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo. Thromb Haemostas 1992; 67: 101-105
16. Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangement of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. J Biol Chem 1996; 271: 2133-2138
17. Dooijewaard G, Kluft C. Stimulation of indigenous fibrinolysis: a novel approach to prevention of thrombosis. In: P. Glas-Greenwalt ed. Fibrinolysis in disease: the malignant process, interventions in thrombogenic mechanisms and novel treatment modalities. New York: CRC-Press, 1995: 233-236
18. Fowkes FG, Lowe GD, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease and risk of coronary heart disease. Lancet 1993;342:84-6.
19. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994;90"2236-40.
20. Lowe GDO, Wood DA, Douglas JT et al. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb Haemostat 1991; 65: 339-343
21. Kluft C. Fibrinolytic shut-down after surgery. In: Fibrinolysis and the central nervous system. Sawaya R., ed. Hanley and Belfus, inc. Philadelphia, 1990: 127-140.
22. Nieuwenhuizen W. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review. Blood Coagul Fibrinol. 1993; 4: 93-96.
23. Eriksson P, Kallin B, van't Hooft FM, Baveholm P, Hamsten A. Allelle-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-55.
24. van der Bom JG, de Knijff P, Bots ML, Haverkate F, Hofman A, Kluft C, Grobbee DE. Polymorphism of the blood clot lysis enzyme tissue type plasminogen activator is associated with myocardial infarction. Circulation 1995;92(Suppl 2):I-30.
25. van den Eijnden-Schrauwen Y, Lakenberg N, Emeis JJ, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator gene does not affect basal endothelial t-PA synthesis. (Letter) Thromb Haemostas 1995;74:1202.